<DOC>
	<DOCNO>NCT02592447</DOCNO>
	<brief_summary>The purpose study evaluate Cognitive Behavioral Intervention Targeted Therapy Fatigue ( CBT-TTF ) fatigue chronic myelogenous leukemia ( CML ) patient tyrosine kinase inhibitor ( TKIs ) feasibility , acceptability potential efficacy relative usual care small-scale randomize controlled trial .</brief_summary>
	<brief_title>Cognitive Behavioral Intervention Targeted Therapy Fatigue ( CBT-TTF ) Intervention</brief_title>
	<detailed_description />
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<criteria>able speak/read English diagnose chronic phase CML treat cancer ( except nonmelanoma skin cancer ) past 5 year care Moffitt Cancer Center ( MCC ) physician stable dose oral TKI &gt; = 3 month new onset worsen fatigue since start TKI report moderatesevere fatigue past week ( FSI average rating &gt; = 4 010 ) clinical history disease ( e.g. , multiple sclerosis , fibromyalgia ) could account fatigue presentation schedule discontinue TKI medical supervision within next 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>CML</keyword>
	<keyword>chronic phase CML</keyword>
	<keyword>leukemia</keyword>
</DOC>